Clinical trial
A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990 is registered in ClinicalTrials.gov with Calluna Pharma AS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Calluna Pharma AS
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 20, 2025
- Completion date
- February 28, 2027
- Enrollment
- 150 (estimated)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.